Press release
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
Real-world Signatera™ analysis and Foresight CLARITY™ results from the HOVON study demonstrate the value of personalized ctDNA testing in therapy response
About this update from Natera, Inc.
[{"type":"text","content":"\nReal-world Signatera™ analysis and Foresight CLARITY™ results from the HOVON study demonstrate the value of personalized ctDNA testing in therapy response assessment and surveillance\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today shared the results from two oral presentations that were presented at the American Society of Hematology (ASH) Annual Meeting.\n\nReal-world Signatera Analysis: Oral Presentation on December 6\n\nA real-world analysis of personalized circulating tumor DNA (ctDNA) detection in lymphoma evaluated 144 patients across 14 lymphoma subtypes, including aggressive and indolent lymphomas and patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy. Signatera was used clinically to assess baseline ctDNA detection, track molecular clearance during first-line (1L) therapy, and evaluate end-of-treatment (EOT) ctDNA status and post-CAR-T response. Key findings included:\n\n\nAcross 14 subtypes of lymphoma, 94% of patients had detectable ctDNA in a pre-treatment sample.\n\n\nctDNA clearance during treatment was highly predictive of CAR-T response (p = 0.0028).\n\n\nRapid ctDNA clearance after one cycle of chemotherapy was more predictive of positive outcomes vs. delayed clearance after two cycles of therapy (HR: 20.95 vs. 7.45).\n\n\nSignatera status at the end of 1L therapy was highly prognostic of event-free survival (HR: 49.77, p","length":2110,"tagName":"div"}]